Correction to previous CEO appointment announcement
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This filing is a correction to a previous announcement regarding the appointment of a new CEO at Arovella Therapeutics Limited. The company clarifies that Nicole Van Der Weerden has been appointed as Chief Executive Officer, effective immediately. This announcement is authorized by the Chair of Arovella Limited.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- 2026 AGM Presentation
- Arovella Appoints CEO
- Complete tumour clearance in gastric cancer animal study
- First Patient Dosed with ALA-101
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics